Clinical trials: Neoadjuvant Treatment
Psoriasis
A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis
The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with plaque-type psoriasis.
- Trial name
- NCT00230529
- Testing
- infliximab
- Volunteers
- 249 people
- Sponsor
- Centocor, Inc.
Breast Cancer
Contrast-enhanced Spectral Mammography (CESM) Early Quantitative Evaluation of Tumoral Response and Pathologic Complete Response Prediction for Localized Breast Cancer Treated by Neoadjuvant Chemotherapy
Some types of localised breast cancer, including stage II and III, HER2 positive (Human Epidermal Growth Factor Receptor) or triple negative cancers are treated with primary or neoadjuvant chemotherapy prior to surgical treatment…
- Trial name
- CERePred (NCT06299202)
- Testing
- Diagnostic test
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Rectal Cancer
Colon Neoadjuvant FOLFOXIRI Study
Objective tumour response rate to FOLFOXIRI to pre-operative therapy.
- Trial name
- NCT01941641
- Testing
- neoadjuvant FOLFOXIRI, Capecitabine
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Non-Small Cell Lung Cancer
Neoadjuvant Chemotherapy Plus/Minus Surgery in Non-Small-Cell Lung Cancer (NSCLC) Stage IIIA/N2
Hypothesis is that surgery is of benefit in locally advanced NSCLC with N2 disease. Patients are randomised to surgery or not.
- Trial name
- NCT00273494
- Testing
- Surgery
- Where
- Denmark
- Volunteers
- 406 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Triple Negative Breast Cancer
Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC
To evaluate the efficacy and safety of P nab-paclitaxel combined with carboplatin versus paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide in the neoadjuvant treatment of triple negative breast…
- Trial name
- NCT04067102
- Testing
- Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide, paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
- Where
- China
- Sponsor
- Hebei Medical University Fourth Hospital
Cancer
Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer
1.To compare overall survival after treatment with the test tri-therapy (TPF: docetaxel plus cisplatin and 5FU) or the control treatment (PF: cisplatin plus 5-FU) followed by chemoradiotherapy in patients with locally advanced…
- Trial name
- NCT00273546
- Testing
- XRP6976 (Docetaxel/Taxotere)
- Where
- 6 sites in United States, Argentina and 4 more
- Volunteers
- 500 people
- Sponsor
- Sanofi
Locally Recurrent Colorectal Cancer
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer
This prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with Bevacizumab plus Anti-PD1 Antibody as neoadjuvant therapy for locally recurrent colorectal cancer
- Trial name
- NCT06881537
- Testing
- Capecitabine, Oxaliplatin, Bevacizumab
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Changzheng Hospital
Ovarian Neoplasms, Fallopian Tube Neoplasms
OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206
A feasibility study of neoadjuvant chemotherapy (NAC) followed by interval cytoreductive surgery (ICS) and postoperative chemotherapy for stage III/IV mullerian carcinomas such as ovarian, tubal and peritoneal carcinomas.
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT00112086
- Testing
- Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)
- Where
- Japan
- Volunteers
- 56 people
- Sponsor
- Japan Clinical Oncology Group
Time
Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell Carcinoma
The optimal interval between neoadjuvant chemradiotherapy and esophagectomy is still a question that needs to be explored for patients with esophageal squamous cell carcinoma.
- Trial name
- NCT06364566
- Testing
- Neoadjuvant chemradiotherapy, Minimally invasive esophagectomy
- Where
- China
- Volunteers
- 303 people
- Sponsor
- Shanghai Zhongshan Hospital
Kidney Transplantation
A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal transplant patients.
- Trial name
- NCT06365437
- Testing
- TCD601, Tacrolimus (TAC), Corticosteroids (CS)
- Where
- 7 sites in Austria, Spain and 1 more
- Volunteers
- 33 people
- Sponsor
- ITB-Med LLC
Acute Myelogenous Leukemia, Myelogenous Leukemia
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety and pharmacokinetics of orally administered venetoclax (ABT-199) combined with decitabine or azacitidine and the preliminary efficacy of…
- Conditions
- Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
- Trial name
- NCT02203773
- Testing
- Posaconazole, ABT-199, Decitabine
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 212 people
- Sponsor
- AbbVie
Thoracic Esophageal Squamous Cell Carcinoma
The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
This is a randomized, open, two arm phase II clinical study. 40 patients are included in the exploratory study. The dominant population with higher biomarker positive / IO score was identified to provide the basis for the later…
- Trial name
- NCT04937673
- Testing
- Camrelizumab+Albumin bound paclitaxel+Cisplatin, Camrelizumab+ Paclitaxel+ Cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Glioblastoma, Gliosarcoma, Adult
A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.
WinGlio is a phase I study investigating neoadjuvant (before surgery) ipilimumab ( a type of immunotherapy drug) in patients with newly diagnosed glioblastoma (a form of brain cancer).
- Conditions
- Glioblastoma, Gliosarcoma, Adult, Glioblastoma - Category
- Trial name
- WinGlio-ipi (NCT07134842)
- Testing
- Ipilimumab (3 mg/kg)
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- University College, London
Gastric Cancer
Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer
Gastric cancer is one of the most common malignant tumors of the digestive tract. Gastric cancer patients diagnosed for the first time in China have a higher proportion of advanced stages and a higher postoperative metastasis…
- Trial name
- NCT04354662
- Testing
- Toripalimab, Docetaxel, Fluorouracil
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Prostate CA
Clinical Study of Geranium Wilfordii Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer
The high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although…
- Trial name
- NCT06861166
- Testing
- Geranium wilfordii combined with androgen deprivation treatment, Androgen deprivation treatment, radical prostatectomy
- Volunteers
- 95 people
- Sponsor
- baotai Liang
Rectal Cancer
Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC
This study aims to evaluate the effectiveness and safety of combining moderately hypofractionated radiotherapy with chemotherapy and anti-PD-1 antibodies as a neoadjuvant treatment for high-risk locally advanced rectal cancer.
- Trial name
- iMHRT-LARC (NCT06599827)
- Testing
- moderately hypofractionated radiotherapy, chemotherapy, immunotherapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai Zhongshan Hospital
Carcinoma, Non-Small-Cell Lung
Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the value of induction Erlotinib therapy before thoracotomy or radiotherapy in ⅢA-N2 (confirmed by mediastinoscopy or PET) non-small cell lung cancer (NSCLC) selected by epidermal growth…
- Trial name
- NCT00600587
- Testing
- neoadjuvant erlotinib therapy, neoadjuvant gemcitabine/carboplatin therapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Guangdong Provincial People's Hospital
Rectal Cancer
Efficacy and Safety Study of Neoadjuvant in Treating Patients With Resectable Local Recurrent Rectal Cancer
RATIONALE: Surgical resection and adjuvant therapy has become the main treatment for resectable local recurrent rectal cancer. However the efficacy and safety of adjuvant therapy is still unknown.
- Trial name
- NARC (NCT01271192)
- Testing
- surgical resection and adjuvant therapy, Neoadjuvant followed by operation
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast…
- Trial name
- NCT01077154
- Testing
- Denosumab
- Where
- 459 sites in United States, Argentina and 37 more
- Volunteers
- 4,509 people
- Sponsor
- Amgen
Multiple Myeloma
Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of the association of Melphalan/Prednisone/Revlimid (MPR) as induction treatment for newly diagnosed myeloma patients over age 65 or those under 65 years who refuse…
- Trial name
- NCT00396045
- Testing
- Revlimid (CC-5013)
- Where
- 9 sites in Italy
- Volunteers
- 54 people
- Sponsor
- University of Turin, Italy
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.